Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Pharmaceutical Sciences|July 29, 2019
PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This SpeciesHans Peter Grimm, Eginhard Schick, Dominik Hainzl, et al.
Frontiers in Immunology|February 21, 2018
Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of Leishmania major, but Not for Spontaneous Cure of Subcutaneous Primary or Secondary L. major InfectionUlrike Schleicher, Jan Liese, Nicole Justies, et al.
Clinical Pharmacology in Drug Development|February 19, 2026
Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy VolunteersDietmar Schwab, Carsten Hofmann, Nicole Justies, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2009
Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitisFaustino Mollinedo, Consuelo Gajate, Ana I Morales, et al.
Plos Neglected Tropical Diseases|August 23, 2017
Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosineJanny A Villa-Pulgarín, Consuelo Gajate, Javier Botet, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 20, 2016
Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion ProteinFranziska Regenass-Lechner, Roland F Staack, Jean-Luc Mary, et al.
Clinical Pharmacology and Therapeutics|May 21, 2024
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting AntibodySara Belli, Maria Amann, Lucy Hutchinson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|April 28, 2011
Characterization of post-surgical alterations in the bile duct-cannulated ratDalila Bachir-Cherif, Denise Blum, Annamaria Braendli-Baiocco, et al.
Bioanalysis|July 29, 2022
Biomarker context-of-use: how organizational design can impact the implementation of the appropriate biomarker assay strategyKyra J Cowan, Michaela Golob, Joanne Goodman, et al.
Frontiers in Oncology|April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposureAnna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Pageof 2